Michael Burry has generally stayed away from investing in biomed and medtech.

This is a claim about degree ('generally'). Test: how much of Burry's disclosed portfolio historically was in biomedical, biotech or medical-technology companies, based on 13F filings (2016 to 2025) and known Scion Capital holdings. True: such positions were rare and small, a small minority of positions and capital across periods. Mostly true: generally rare, with one or two notable exceptions. Mixed: such positions appeared often but were not dominant. Mostly false: biomed or medtech positions were recurring and sometimes significant. False: the sector was a frequent or major focus of his holdings.

Set before the research began.

1. E1 primary_doc.xml (Scion Asset Management Form 13F-HR, period 12-31-2020) U.S. Securities and Exchange Commission (EDGAR) · 16 February 2021

   “As of 12/31/20, Scion Asset Management held Pfizer, Inc. long call options, which are included in this 13F.”

2. E2 Michael Burry's Top Current Stock Picks in 2025 - New Trader U New Trader U · 20 August 2025

   “Regeneron makes up 14 percent of Burry’s holdings and has been one of his more successful recent purchases.”

3. E3 Michael Burry Portfolio | Most Recent Holdings & Activity MarketGenius

   “CI | The Cigna Group | 6.93% | Add 10.00% | 2023 Q1 | 27,500 | 280.60 USD | 7.72M USD”

4. E4 Michael Burry - Scion Asset Management, LLC Portfolio Stock Holdings | Quiver Quantitative Quiver Quantitative

   “Scion Asset Management, LLC disclosed 9 stock positions in a recent SEC 13F filing. $68,138,076 of stock holdings were filed, with the largest holdings including MOH, LULU, and SLM.”

5. E5 0001567619-20-019679.txt U.S. Securities and Exchange Commission (EDGAR), Scion Asset Management 13F-HR · 16 November 2020 Own record

   “<nameOfIssuer>PFIZER INC</nameOfIssuer> <titleOfClass>COM</titleOfClass> <cusip>717081103</cusip> <value>15289</value>”

6. E6 Scion Asset Management, LLC 13F Filings 13f.info

   “| Q2 2025 | 15 | 578,337 | UNH calls, REGN calls, LULU calls, META calls | 13F-HR | 8/14/2025 | 000187920225000038 |”

7. E7 Scion Asset Management, LLC 13F Filings 13f.info

   “| Q1 2022 | 12 | 201,379 | AAPL puts, BMY, BKNG, DISCK | 13F-HR | 5/16/2022 | 000156761922010747 |”

8. E8 Michael Burry portfolio: holdings and latest trades MEDGE Capital · 3 November 2025

   “54% of the 13F portfolio is in health care, followed by consumer discretionary at 26%.”

Scion's 13F filings show biopharma positions in several periods. Pfizer stock and call options appear in the 2020 filings (E5, E1), Bristol-Myers Squibb in Q1 2022 (E7), and Regeneron calls in Q2 2025 (E6). E2 says Regeneron alone made up 14 percent of holdings. E3 and E6 list health-care holdings such as Cigna and UnitedHealth calls, and E8 reports a 54% health-care weighting without saying which companies make it up. So biomed holdings recur and were sometimes large, but on this evidence they were not a dominant focus. Because the evidence covers only some quarters, how often they appeared cannot be fully measured.